In this study, we investigated the biological role and potential therapeutic implication of SHP-1 in DLBCL. SHP-1 agonists increased SHP-1 activity, whereas downregulated Lyn signaling. The gene discussed is LYN; the disease is diffuse large B-cell lymphoma.